These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 37180779)

  • 1. The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease.
    Qin L; Wu J; Sun X; Huang X; Huang W; Weng C; Cai J
    Front Cardiovasc Med; 2023; 10():1119005. PubMed ID: 37180779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease.
    Baars T; Gieseler RK; Patsalis PC; Canbay A
    Metabolism; 2022 May; 130():155179. PubMed ID: 35283187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.
    Lim S; Oh TJ; Koh KK
    Int J Cardiol; 2015 Dec; 201():408-14. PubMed ID: 26310987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review.
    Stahl EP; Dhindsa DS; Lee SK; Sandesara PB; Chalasani NP; Sperling LS
    J Am Coll Cardiol; 2019 Mar; 73(8):948-963. PubMed ID: 30819364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organokines in disease.
    Chung HS; Choi KM
    Adv Clin Chem; 2020; 94():261-321. PubMed ID: 31952573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases.
    Vural H; Armutcu F; Akyol O; Weiskirchen R
    Clin Chim Acta; 2021 Dec; 523():374-379. PubMed ID: 34678296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
    Cai J; Zhang XJ; Ji YX; Zhang P; She ZG; Li H
    Circ Res; 2020 Feb; 126(5):679-704. PubMed ID: 32105577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
    Lim S; Taskinen MR; Borén J
    Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
    Luo J; Xu L; Li J; Zhao S
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):193-9. PubMed ID: 25563143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Adams LA; Anstee QM; Tilg H; Targher G
    Gut; 2017 Jun; 66(6):1138-1153. PubMed ID: 28314735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease.
    Yang B; Yang X; Tan X; Lu L; Fan W; Barbier-Torres L; Steggerda J; Liu T; Yang H
    Can J Gastroenterol Hepatol; 2022; 2022():6799414. PubMed ID: 36397950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
    Choudhary NS; Duseja A
    J Clin Exp Hepatol; 2019; 9(4):506-514. PubMed ID: 31516267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.
    Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A
    Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart.
    Dogru T; Kirik A; Gurel H; Rizvi AA; Rizzo M; Sonmez A
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.
    Fargion S; Porzio M; Fracanzani AL
    World J Gastroenterol; 2014 Oct; 20(37):13306-24. PubMed ID: 25309067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease.
    Josloff K; Beiriger J; Khan A; Gawel RJ; Kirby RS; Kendrick AD; Rao AK; Wang RX; Schafer MM; Pearce ME; Chauhan K; Shah YB; Marhefka GD; Halegoua-DeMarzio D
    J Cardiovasc Dev Dis; 2022 Nov; 9(12):. PubMed ID: 36547416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.